Home Health Wellness Wellness on May 2, 2022 Researchers at the Indian Institute of Technology (IIT) in Mandi have identified a drug molecule which triggers the release of insulin by the pancreas and can potentially be used as an orally administered medicine for diabetes. According to the research team, the molecule is called PK2 and the findings of the research have been published in the Journal of Biological Chemistry. “Current drugs such as exenatide and liraglutide used for diabetes are administered as injections, and they are costly and unstable after administration. We seek to find simpler drugs that are stable, cheap, and effective against both Type 1 and Type 2 diabetes,” said Prosenjit Mondal, Associate Professor, School of Basic Sciences at the IIT. Diabetes is associated with insufficient insulin release by beta cells of the pancreas in response to blood glucose levels. The release of insulin entails many intricate biochemical processes. One such process involves protein structures called GLP1R present in the cells. A hormonal molecule called GLP1, released after the ingestion of a meal, binds to the GLP1R and triggers the release of insulin. Drugs such as exenatide and liraglutide mimic GLP1 and bind to GLP1R to trigger insulin… Read full this story
- Discover Alternative Medicine Treatment For Rheumatoid Arthritis
- Diabetes Test and Control
- Gestational Diabetes - A Cause For Concern In Pregnancy
- Diabetes Mellitus - Signs Symptoms and Risks
- Diabetes - Treating a Worldwide Pandemic with Hypnosis Therapy
- Diabetes - Oxidative Stress and Metabolic Memory Control
- Discover Vitamins and Herbs for Diabetics
- Treating Erectile Dysfunction In Diabetics: Can Gene Therapy Equalize Viagra Efficacy?
- A Look At Natural Cures For Type 1 Diabetes
- Diabetes Etiquette - What You Don't Say Does Matter
IIT-Mandi Team Discovers Molecule That Can Be Used For The Treatment Of Diabetes have 273 words, post on www.boldsky.com at May 2, 2022. This is cached page on Drudgereport. If you want remove this page, please contact us.